This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Raltitrexed

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Raltitrexed is an inhibitor of thymidylate synthase. It is licensed for use as monotherapy when fluorouracil-based palliative therapy for colorectal cancer is inappropriate or not tolerated (1).

Adverse effects:

  • raltitrexed is more likely than infused fluorouracil/folinic acid to cause severe nausea, diarrhoea, anorexia, lethargy, neutropenia and thrombocytopenia (1)
  • if raltitrexed is used then monitoring of renal function is essential (dose should be adjusted if creatinine clearance is below 65 mL/minute) (1)

Reference:

  1. Drug and Therapeutics Bulletin (2002), 40(7), 50-2.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.